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BSTRACT
 
Background
 
Only 15 to 20 percent of patients
with chronic hepatitis C have a sustained virologic
response to interferon therapy. We compared the ef-
ficacy and safety of recombinant interferon alfa-2b
alone with those of a combination of interferon alfa-
2b and ribavirin for the initial treatment of patients
with chronic hepatitis C.
 
Methods
 
We randomly assigned 912 patients with
chronic hepatitis C to receive standard-dose interfer-
on alfa-2b alone or in combination with ribavirin
(1000 or 1200 mg orally per day, depending on body
weight) for 24 or 48 weeks. Efficacy was assessed by
measurements of serum hepatitis C virus (HCV) RNA
and serum aminotransferases and by liver biopsy.
 
Results
 
The rate of sustained virologic response
(defined as an undetectable serum HCV RNA level 24
weeks after treatment was completed) was higher
among patients who received combination therapy
for either 24 weeks (70 of 228 patients, 31 percent)
or 48 weeks (87 of 228 patients, 38 percent) than
among patients who received interferon alone for
either 24 weeks (13 of 231 patients, 6 percent) or 48
weeks (29 of 225 patients, 13 percent) (P<0.001 for
the comparison of interferon alone with both 24 weeks
and 48 weeks of combination treatment). Among pa-
tients with HCV genotype 1 infection, the best re-
sponse occurred in those who were treated for 48
weeks with interferon and ribavirin. Histologic im-
provement was more common in patients who were
treated with combination therapy for either 24 weeks
(57 percent) or 48 weeks (61 percent) than in those
who were treated with interferon alone for either 24
weeks (44 percent) or 48 weeks (41 percent). The drug
doses had to be reduced and treatment discontinued
more often in patients who were treated with combi-
nation therapy.
 
Conclusions
 
In patients with chronic hepatitis C,
initial therapy with interferon and ribavirin was more
effective than treatment with interferon alone. (N Engl
J Med 1998;339:1485-92.)
 
©1998, Massachusetts Medical Society.
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HRONIC hepatitis C infection is now rec-
ognized as an important health care prob-
lem.
 
1
 
 Nearly 4 million Americans are esti-
mated to be infected, and cirrhosis will
eventually develop in at least 15 to 20 percent of
them.
 
2-5
 
 In the United States, infection with hepatitis
C virus (HCV) is a leading cause of chronic liver dis-
ease and the most common indication for liver trans-
plantation.
 
1,6
 
Until recently, interferon alfa was the only thera-
py available for patients with chronic hepatitis C.
However, after 48 weeks of treatment, serum HCV
RNA levels are undetectable in only 15 to 20 per-
cent of patients.
 
7-12
 
 Pilot studies of patients who have
relapsed and of previously untreated patients suggest
that combining interferon with ribavirin is more ef-
fective than using interferon alone,
 
13,14
 
 and in a
small, placebo-controlled study of previously un-
treated patients, treatment with interferon and riba-
virin for six months was more effective than inter-
feron alone.
 
15
 
The aims of this study were to compare the safety
and efficacy of interferon alone and in combination
with ribavirin for the initial treatment of chronic
hepatitis C and to determine the optimal duration
of combination therapy.
C
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METHODS
 
Selection of Patients
 
Adult patients were eligible for the study if they were seroposi-
tive for HCV RNA on testing with the polymerase chain reaction,
had undergone a liver biopsy within one year before entry whose
results were consistent with a diagnosis of chronic hepatitis, and had
had elevated serum alanine aminotransferase values (more than
the upper limit of normal values) for at least six months. Patients
with decompensated cirrhosis,
 
16
 
 serum alpha-fetoprotein concentra-
tions of more than 50 ng per milliliter, anemia (hemoglobin con-
centration, less than 12 g per deciliter in women and less than 13 g
per deciliter in men), human immunodeficiency virus infection,
psychiatric conditions, seizure disorders, cardiovascular disease, he-
mophilia, poorly controlled diabetes mellitus, or autoimmune dis-
eases were excluded, as were those who had undergone organ trans-
plantation and those who were unable to practice contraception.
 
Study Design and Organization
 
This double-blind, placebo-controlled trial was conducted at
44 centers in the United States. The study was approved by the
institutional review board at each center, and all the patients pro-
vided written informed consent. We screened 1337 patients, of
whom 404 did not meet the inclusion criteria. The remaining
933 patients were randomly assigned to one of four treatment
groups, which were balanced for the presence or absence of cir-
rhosis, pretreatment serum HCV RNA level, and HCV genotype.
The analysis was based on the 912 patients who received at least
one dose of medicine (21 patients were randomly assigned to a
treatment group but did not receive therapy: 13 did not wish to
continue, 5 did not meet the entry criteria, and 3 had adverse
events before the initiation of therapy). Enrollment began in
April 1996, and the trial was completed in March 1998.
The patients were randomly assigned to a treatment group as
follows: recombinant interferon alfa-2b (Intron A, Schering-
Plough, Kenilworth, N.J.) plus placebo for 24 weeks in the case
of 231 patients and for 48 weeks in the case of 225 patients, and
the combination of interferon alfa-2b and ribavirin (Rebetron,
Schering-Plough) for 24 weeks in the case of 228 patients and for
48 weeks in the case of 228 patients. Interferon alfa-2b was given
subcutaneously in a dose of 3 million units three times per week,
and ribavirin (or matched placebo) was administered orally twice
a day at a total daily dose of 1000 mg for patients who weighed
75 kg or less and 1200 mg for those who weighed more than
75 kg. Both drugs were started and stopped at the same time.
The severity of adverse events was graded as mild, moderate,
severe, or life-threatening
 
17
 
; therapy was discontinued after life-
threatening events. For severe adverse events other than anemia,
the dose of interferon alfa-2b was reduced to 1.5 million units
three times a week and the dose of ribavirin was reduced to 600 mg
per day. The full dose could be resumed after the event or dis-
continued if the effect persisted. The dose of ribavirin was re-
duced to 600 mg per day in patients whose hemoglobin concen-
trations fell below 10 g per deciliter, and it was discontinued if
the concentration fell below 8.5 g per deciliter.
The patients were evaluated as outpatients at weeks 1, 2, 4, 6,
and 8 and then every 4 weeks during treatment and 4, 8, 12, and
 
*Plus–minus values are means ±SD. Because of rounding, percentages may not total 100. None
of the differences among the groups were significant.
†The duration of infection was estimated from the date of transfusion or initial exposure to other
parenteral sources, and it could not be calculated for patients with sporadic infection or those in
whom the source of infection was unknown.
‡Scores could range from 0 to 18, with higher scores indicating more severe abnormalities.
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24 
 
WK
 
(
 
N
 
=231)
48 
 
WK
 
(
 
N
 
=225)
24 
 
WK
 
(
 
N
 
=228)
48 
 
WK
 
(
 
N
 
=228)
Age — yr 45±7 44±8 44±8 44±8
Sex — M/F 154/77 150/75 148/80 152/76
Weight — kg 83.9±17.0 83.3±16.3 83.7±18.1 80.8±17.9
Serum alanine aminotransferase — 
no. of times upper limit of normal
4.0±2.9 3.7±2.5 4.1±2.8 3.7±2.3
Serum aspartate aminotransferase —
no. of times upper limit of normal
2.9±2.3 2.7±1.7 2.9±2.2 2.7±1.7
Serum HCV RNA
No. of copies/ml — ¬10
 
¡6
 
>2¬10
 
6
 
 copies/ml — no. (%)
5.0±5.0
157 (68)
4.8±4.6
162 (72)
5.1±5.8
166 (73)
5.7±7.5
152 (67)
Estimated duration of infection — yr† 18.5±9.1 18.8±9.5 18.9±9.8 19.6±9.6
Source or type of infection — no. (%)
Transfusion
Intravenous drug use
Sporadic or unknown
41 (18)
124 (54)
66 (29)
54 (24)
115 (51)
56 (25)
55 (24)
106 (46)
67 (29)
49 (21)
127 (56)
52 (23)
Genotype — no. (%)
1
2
3
Other
167 (72)
38 (16)
24 (10)
2 (1)
162 (72)
43 (19)
19 (8)
1 (0.4)
164 (72)
29 (13)
28 (12)
7 (3)
166 (73)
37 (16)
23 (10)
2 (1)
Knodell score‡ 7.4±2.7 7.6±2.6 7.5±2.5 7.3±2.8
Cirrhosis — no. (%) 15 (6) 10 (4) 9 (4) 15 (7)
Bridging fibrosis — no. (%) 50 (22) 61 (27) 50 (22) 40 (18)
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24 weeks after therapy. Biochemical and hematologic testing was
performed by a central laboratory. Serum HCV RNA levels were
determined before treatment; during treatment at weeks 4, 12,
and 24; at 36 and 48 weeks in the patients who were treated for
48 weeks; and after therapy at weeks 12 and 24. Serum HCV RNA
was measured by a reverse-transcription–polymerase-chain-reaction
assay with a sensitivity of 100 copies per milliliter (National Ge-
netics Institute, Los Angeles).
 
18
 
 HCV genotyping was performed
as previously described.
 
19
 
 Liver biopsy was performed 24 weeks
after the end of treatment, and the specimens were analyzed by a
single pathologist who was unaware of the patients’ identification,
treatment regimen, and response and of the timing of the biopsy
in relation to treatment.
 
Assessment of Efficacy
 
The primary end point was a sustained virologic response, de-
fined as the absence of serum HCV RNA 24 weeks after treat-
ment was completed. Secondary end points were normalization
of the serum alanine aminotransferase concentration and histo-
logic improvement. The degree of hepatic inflammation and fi-
brosis was graded with a modified Knodell Histologic Activity
Index.
 
20
 
 The inflammation score was obtained by combining the
scores for the first three components of this index: portal,
periportal, and lobular inflammation. The scores could range
from 0 to 18, with higher scores indicating more severe abnor-
malities. The degree of fibrosis was graded as 0, no fibrosis;
1, portal fibrosis; 3, bridging fibrosis; or 4, cirrhosis. Histologic
improvement was defined as a decrease of at least two points in
the inflammation score, as compared with the score for the pre-
treatment biopsy specimen. The biochemical response and the
sustained combined biochemical and virologic response were also
assessed.
 
1
 
Statistical Analysis
 
The study was designed to have 220 patients per group in order
to have a power of 89 percent to detect a difference of 15 per-
centage points between the rates of sustained virologic response
(30 percent vs. 45 percent), at a 5 percent level of significance
(with two-sided tests). The treatment responses were compared
with the use of Fisher’s exact test.
 
21
 
 Changes in the liver-biopsy
score within each group were compared with the use of Student’s
t-tests.
 
21
 
 The relation between pretreatment variables and treat-
ment response was examined by stepwise logistic-regression analy-
sis.
 
22
 
 All P values are two-tailed.
 
RESULTS
 
Characteristics of the Patients
 
The base-line characteristics of the patients in the
four groups were similar (Table 1). The proportion
of patients with HCV genotype 1 (72 percent) was
similar to the proportions in prior reports from the
United States.
 
23,24
 
Virologic Response
 
At the end of follow-up, the rates of virologic re-
sponse were higher among the patients who had been
treated with interferon and ribavirin for 24 weeks
(31 percent) or 48 weeks (38 percent) than among
those who had received interferon alone for 48
weeks (13 percent, P<0.001) (Table 2). Increasing
the duration of combination therapy from 24 weeks
 
*A virologic response was defined as the absence of serum HCV RNA (limit of detection, 100
copies per milliliter), and a biochemical response was defined as a normalization of the serum alanine
aminotransferase concentration. Responses were assessed in the last week of treatment and 24 weeks
later. CI denotes confidence interval. 
†P<0.001 for the comparison with either interferon group.
‡P=0.05 for the comparison with 24 weeks of interferon and ribavirin.
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24 
 
WK
 
48 
 
WK
 
24 
 
WK
 
48 
 
WK
 
Virologic response
 
End of treatment
No. with response/
total no. treated
Percent (95% CI)
66/231
29 (23–34)
54/225
24 (18–30)
121/228
53 (47–60)†
115/228
50 (44–57)†
End of follow-up
No. with response/
total no. treated
Percent (95% CI)
13/231
6 (3–9)
29/225
13 (9–17)
70/228
31 (25–37)†
87/228
38 (32–45)†‡
 
Biochemical response
 
End of treatment
No. with response/
total no. treated
Percent (95% CI)
56/231
24 (19–30)
62/225
28 (22–33)
133/228
58 (52–65)†
149/228
65 (54–67)†
End of follow-up
No. with response/
total no. treated
Percent (95% CI)
25/231
11 (7–15)
35/225
16 (11–20)
72/228
32 (25–38)†
83/228
36 (30–43)†
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to 48 weeks increased the rate of virologic response
from 31 percent to 38 percent (P=0.05). The rates
of response at the completion of 24 weeks of therapy
were almost twice as high in the combination-therapy
group as in the interferon-alone group (53 percent
vs. 29 percent, P<0.001), and the respective rates af-
ter 48 weeks of therapy were more than twice as
high (50 percent vs. 24 percent, P<0.001). Relapse
after therapy was less frequent with combination
therapy (42 percent at 24 weeks and 24 percent at
48 weeks) than with interferon alone (80 percent at
24 weeks and 46 percent at 48 weeks).
In patients who were treated with interferon
alone, viral clearance at week 4 was associated with
a sustained virologic response, as reported previous-
ly.
 
25-27
 
 However, among 51 of the 87 patients (59
percent) who were treated with combination therapy
for 48 weeks and who eventually had sustained re-
sponses, HCV RNA remained detectable in serum
until week 12 or 24 of therapy. Late viral clearance
with a subsequent sustained response was also ob-
served in 50 percent of patients (35 of 70 patients)
who were treated with interferon and ribavirin for
24 weeks, 23 percent of those (3 of 13 patients) who
received interferon alone for 24 weeks, and 52 per-
cent of those (15 of 29 patients) who received inter-
feron alone for 48 weeks.
 
Biochemical Response
 
The rate of sustained biochemical response was
higher among patients who received interferon and ri-
bavirin for 24 or 48 weeks than among those who
received interferon alone for 24 or 48 weeks (Table 2).
The combined rates of sustained biochemical and
virologic responses in the groups given interferon
and ribavirin were 26 percent (60 of 228 patients) in
the group treated for 24 weeks and 34 percent (77
of 228 patients) in the group treated for 48 weeks,
as compared with 5 percent (12 of 231 patients,
P<0.001) in the group treated with interferon for 24
weeks and 12 percent (27 of 225 patients, P<0.001)
in the group treated with interferon for 48 weeks.
Normalization of serum alanine aminotransferase
values was associated with undetectable levels of
serum HCV RNA in most patients who had sus-
tained virologic responses. Of 199 patients who had
a sustained virologic response, 176 (88 percent) had
persistently normal serum alanine aminotransferase
concentrations. The mean (±SD) elevations of serum
alanine aminotransferase after therapy in the remain-
ing 23 patients (12 percent) was 1.6±0.1 times the
upper limit of the normal value. Eighteen percent of
patients (39 of 215) with a sustained biochemical re-
sponse had persistently detectable serum HCV RNA.
The proportion of patients who had sustained viro-
logic responses among those with a sustained bio-
chemical response was higher in the combination-
therapy group as a whole (137 of 155 patients, 88
percent) than in the interferon group as a whole (39
of 60 patients, 65 percent).
 
Histologic Response
 
Pretreatment and post-treatment liver-biopsy spec-
imens were available from 670 patients (73 percent).
Histologic improvement occurred in all four groups,
but it was more common in either combination-
therapy group than in the interferon group that was
treated for 48 weeks (P<0.001) (Table 3). The de-
gree of histologic improvement, defined as a de-
crease in the inflammatory score of at least two
points, was greatest in the group given interferon
and ribavirin for 48 weeks. Of the 165 patients who
had a sustained virologic response and who had pre-
treatment and post-treatment biopsy specimens avail-
able, 142 (86 percent) had a decrease in hepatic in-
flammation regardless of the treatment regimen.
Inflammation also decreased in 194 of 497 patients
(39 percent) who had persistent viremia at follow-
up. Treatment had no effect on fibrosis.
 
*The numbers of patients are the numbers with pretreatment and post-
treatment biopsy specimens. 
†Scores could range from 0 to 18, with higher scores indicating more
severe abnormalities. Improvement was defined as a decrease in the inflam-
mation score of at least two points, no change as an increase or decrease
of one point, and worsening as an increase of at least two points.
‡P=0.005 for the comparison with 48 weeks of treatment with interfer-
on alone.
§P<0.001 for the comparison with 48 weeks of treatment with interfer-
on alone.
¶Scores could range from 0 (no fibrosis) to 4 (cirrhosis). Improvement
was defined as a decrease of at least one point in the score.
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24 WK
(N=176)
48 WK
(N=158)
24 WK
(N=179)
48 WK
(N=157)
Change in inflammation score†
All patients
Percent with improvement
Mean change
44
¡0.6
41
¡1.0
57
¡1.8‡
61
¡2.4§
Patients with a response
Percent with improvement
Mean change
89
¡3.8
78
¡5.2
88
¡4.4
86
¡4.5
Patients with a relapse or no
response
Percent with improvement
Mean change
41
¡0.4
35
¡0.3
41
¡0.6
39
¡0.5
Change in fibrosis score¶
All patients
Percent with improvement
Mean change
11
0.1
17
¡0.1
16
0.0
14
0.0
Patients with a response
Percent with improvement
Mean change
11
¡0.2
26
¡0.2
24
¡0.2
16
¡0.1
Patients with a relapse or no 
response
Percent with improvement
Mean change
11
0.1
16
0.0
12
0.2
12
0.2
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Variables Associated with a Response
Treatment with interferon and ribavirin was the
strongest predictor of a response. Sustained virolog-
ic response was unrelated to age, sex, body weight,
or the estimated duration of disease. The response
rates for pretreatment variables known to influence
the response to treatment are shown in Table 4.
Among patients with HCV genotype 1 infection
who were treated for 48 weeks, the rate of sustained
response for patients who were treated with interfer-
on and ribavirin was four times as high as that in pa-
tients who were treated with interferon alone for 48
weeks. Among patients with this genotype, 48 weeks
of combination therapy was more beneficial than 24
weeks of combination therapy (46 of 166 patients
[28 percent] had a response, as compared with 26
of 164 patients [16 percent]; P=0.01). The response
rates for patients with HCV genotype 1a infections
and those with genotype 1b infections were similar.
Among patients with other HCV genotypes who
were treated with combination therapy, the response
rates did not vary significantly as a function of the
duration of therapy. The results in patients with
HCV genotype 2 were similar to those in patients
with HCV genotype 3.
Regardless of the viral load at base line or the
presence of cirrhosis or bridging fibrosis at base line,
the response was better in patients who were treated
with interferon and ribavirin. Among patients with
a high viral load or fibrosis at base line, the response
rates were two to five times as high in those who were
treated with interferon and ribavirin for either 24 or
48 weeks as in those who were treated with interfer-
on alone for 48 weeks. The response of patients with
HCV genotypes other than 1 who were treated with
24 or 48 weeks of combination therapy were similar
irrespective of the base-line viral load, whereas the
response of patients with HCV genotype 1 and high
pretreatment viral loads was better among those
who received 48 weeks of combination therapy than
among those who received 24 weeks of therapy.
Stepwise logistic-regression analyses revealed that
greater efficacy was associated with HCV genotypes
other than 1 (P<0.001), a base-line viral load of
2¬106 copies per milliliter or less (P<0.001), the ab-
sence of cirrhosis at base line (P=0.04), and female
sex (P=0.05), in addition to combination treatment
(P<0.001) and 48 weeks of therapy (P=0.002).
Safety
Hemoglobin concentrations decreased to less
than 10 g per deciliter, necessitating a reduction in
the dose of ribavirin, in 8 percent of the patients
who were treated with combination therapy (Table
5). The mean maximal decrease from base line was
3.1 g per deciliter (range of changes, ¡7.0 to +0.2)
after four weeks of therapy, and this was associated
with compensatory reticulocytosis. A reduction in the
dose resulted in an increase in hemoglobin concen-
trations of 1 to 1.5 g per deciliter, and the concentra-
tions were subsequently stable throughout treatment.
Both hemoglobin concentrations and reticulocyte
counts returned to base line within 4 to 8 weeks af-
ter treatment was discontinued at 24 or 48 weeks.
The longer duration of therapy was not associated
with a significantly higher incidence of reductions in
*P=0.01 for the comparison with interferon alone for 48 weeks.
†P<0.001 for the comparison with interferon alone for 48 weeks.
‡P=0.06 for the comparison with interferon alone for 48 weeks.
§P=0.04 for the comparison with interferon alone for 48 weeks.
¶Fibrosis was defined as a score of 3, and cirrhosis as a score of 4. The degree of fibrosis could not be adequately
evaluated in the pretreatment biopsy specimens of 54 patients.
TABLE 4. RATES OF SUSTAINED VIROLOGIC RESPONSE ACCORDING TO PRETREATMENT VARIABLES 
AND TREATMENT GROUP.
VARIABLE
NO. OF
PATIENTS INTERFERON INTERFERON AND RIBAVIRIN
24 WK 48 WK 24 WK 48 WK
no./total no. of patients (%)
Genotype
1
Other
659
253
3/167 (2)
10/64  (16)
11/162 (7)
18/63  (29)
26/164 (16)*
44/64  (69)†
46/166 (28)†
41/61  (66)†
Base-line serum HCV RNA level
>2¬106 copies/ml
«2¬106 copies/ml
637
275
6/157 (4)
7/74  (9)
11/162 (7)
18/63  (29)
44/166 (27)†
26/62  (42)‡
54/152 (36)†
33/76  (43)§
Degree of fibrosis at base line¶
Cirrhosis or bridging fibrosis
Minimal or no fibrosis
250
608
3/65  (5)
7/154 (5)
9/71  (13)
18/136 (13)
17/59  (29)*
51/159 (32)†
21/55  (38)†
62/159 (39)†
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therapy, remaining above 100¬103 per cubic millime-
ter in 95 to 98 percent of all patients.
Dyspnea, pharyngitis, pruritus, rash, nausea, insom-
nia, and anorexia were more common with combi-
nation therapy than with interferon alone (Table 5).
The incidence of side effects was higher after 48 weeks
of treatment than after 24 weeks of treatment, re-
gardless of the type of therapy.
The drug doses were reduced because of adverse
events other than anemia in 13 percent of patients
who were given interferon and ribavirin for 24 weeks
and in 17 percent of those who were treated for 48
weeks. Among the patients who were given interfer-
on alone, the dose was reduced in 12 percent of
those who were treated for 24 weeks and in 9 per-
cent of those who were treated for 48 weeks. The
most frequent reason for the discontinuation of ther-
apy in all groups was emotional disturbance — mainly
depression; the frequency of cessation of treatment
for depression ranged from 2 to 9 percent in the
four groups.
DISCUSSION
The currently approved initial therapy for patients
with chronic HCV infection consists of treatment
with interferon for at least 48 weeks. The rates of
sustained virologic response with this regimen are
approximately 15 to 20 percent.7-12 Our results con-
firm this low response rate.
We found that combination therapy with interfer-
on and ribavirin for either 24 or 48 weeks was su-
perior to therapy with interferon alone with respect
to virologic, biochemical, and histologic end points.
The higher rates of sustained virologic response
were the result of higher rates of response at the end
of treatment and, subsequently, lower rates of re-
lapse. Recent reports suggest that similar sustained
virologic responses are usually long-lasting (5 to 10
years) and are accompanied by progressive histolog-
ic improvement.28,29 In our study, late clearance of
HCV RNA from serum during combination therapy
was also frequently associated with a sustained re-
sponse. This phenomenon is uncommon in patients
who are treated with interferon alone, which suggests
that stopping therapy at week 12 because of persist-
ent viremia, as recently suggested,1,18,30 may not be
appropriate in the case of therapy with interferon and
ribavirin.
The beneficial effect of combination therapy also
extended to subgroups of patients in whom treatment
has historically been unsuccessful, such as patients
with HCV genotype 1 infection, high pretreatment
viral burdens, or advanced fibrosis or cirrhosis. Ap-
proximately 70 percent of U.S. patients with chronic
HCV have genotype 1 infection, and such patients
derived the greatest benefit from combination ther-
apy for 48 weeks, suggesting that HCV genotyping
should be considered before treatment is initiated.
*Only events that occurred in at least 10 percent of patients are included.
†The daily dose of ribavirin was reduced to 600 mg for patients with he-
moglobin values below 10 g per deciliter, and treatment with ribavirin was
discontinued in patients with hemoglobin values below 8.5 g per deciliter.
‡In the case of other severe events, the dose of interferon was decreased
to 1.5 million units three times a week and the dose of ribavirin was de-
creased to 600 mg per day.
TABLE 5. RATES OF DISCONTINUATION OF TREATMENT, 
DOSE REDUCTIONS, AND OTHER ADVERSE EVENTS 
DURING TREATMENT.*
ADVERSE EVENT INTERFERON
INTERFERON 
AND RIBAVIRIN
24 WK
(N=231)
48 WK
(N=225)
24 WK
(N=228)
48 WK
(N=228)
percent
Discontinuation of treatment for 
any severe event
9 14 8 21
Dose reduction
Due to anemia†
Due to other adverse events‡
0
12
0
9
7
13
9
17
Influenza-like symptoms
Headache
Fatigue
Malaise
Myalgia
Arthralgia
Musculoskeletal pain
Fever
63
62
7
57
27
26
35
67
72
5
63
36
32
40
63
68
4
61
30
20
37
66
70
11
64
33
28
41
Gastrointestinal symptoms
Anorexia
Dyspepsia
Vomiting
Nausea
Diarrhea
Abdominal pain
16
6
10
35
22
17
19
9
13
33
26
20
27
14
11
38
18
15
25
16
9
46
22
14
Psychiatric symptoms
Anxiety
Impaired concentration
Depression
Emotional lability
Insomnia
Irritability
9
14
25
6
27
19
13
14
37
8
30
27
10
11
32
7
39
23
18
14
36
11
39
32
Respiratory tract symptoms
Cough
Dyspnea
Pharyngitis
Sinusitis
5
9
9
7
9
10
10
14
15
19
11
9
14
18
20
10
Dermatologic symptoms
Alopecia
Pruritus
Rash
Dry skin
Inflammation at injection site
27
9
9
4
10
28
8
8
8
14
28
21
20
8
13
32
19
28
15
12
the dose of ribavirin due to anemia. Discontinuation
of therapy and transfusion were necessary in one pa-
tient with a hemoglobin concentration of less than
10 g per deciliter. Reductions in the dose of ribavirin
and subsequent completion of treatment did not af-
fect the rate of sustained response. Leukocyte counts
decreased in all groups during therapy, but the mean
value remained within the normal range. The mean
platelet counts were similar at base line and during
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Ribavirin, a synthetic guanosine analogue, has ac-
tions in vitro against a range of RNA and DNA vi-
ruses.31 When given alone to patients with chronic
hepatitis C, ribavirin decreases serum aminotransfer-
ase concentrations but has no antiviral effect.32-34 Ri-
bavirin has been postulated to inhibit viral-depend-
ent RNA polymerase, the capping structure of viral
messenger RNA, and inosine monophosphate dehy-
drogenase.31 Other immunomodulatory actions may
also contribute to the drug’s beneficial effects.35 De-
spite these potential actions, the exact mechanism re-
sponsible for the improved response that occurs when
ribavirin is combined with interferon is unknown.
Combination therapy was relatively safe, but mod-
ifications in the dose and discontinuation of treatment
were required more often in patients who received
interferon and ribavirin than in those who were
treated with interferon alone. Reversible, hemolytic
anemia due to ribavirin occurred, as has been previ-
ously reported when this drug was given alone.32-34
Patients who are treated with ribavirin should there-
fore be monitored closely (hemoglobin should be
measured two and four weeks after therapy is begun
and then as clinically indicated). The symptoms relat-
ed to treatment with interferon and ribavirin have
been reported previously, and there were no syner-
gistic effects. Cough, pruritus, rash, and insomnia, all
of which have been associated with the use of other,
similar nucleoside analogues, were more common in
the patients who received combination therapy.
In summary, in patients with chronic hepatitis C,
therapy with interferon and ribavirin is more effec-
tive than interferon alone in inducing virologic and
histologic improvement, and the combination may
therefore be indicated as initial therapy in such pa-
tients.
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